Effect of bulevirtide (BLV) monotherapy 2 mg/day for 48 weeks on HDV RNA levels and ALT levels in 18 patients with HDV-related cirrhosis and clinically significant portal hypertension. Credit: Journal of Hepatology In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus...
by Nicola Wittekindt, Deutsches Zentrum für Infektionsforschung Transmission electron micrograph image of hepatitis B virus particles. Credit: Betty Partin/CDC Between 10 and 20 million people worldwide are infected with hepatitis D virus (HDV). HDV infection is always associated with hepatitis B virus infection. So far there has been no satisfactory therapeutic option for this most...
